Live feed08:30:00·2dPRReleasevia QuantisnowCadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)ByQuantisnow·Wall Street's wire, on your screen.CVKD· Cadrenal Therapeutics Inc.Health Care
